AB1426-PARE THE GLOBAL OSTEOARTHRITIS PATIENT PERCEPTION SURVEY (GOAPPS): A PILOT STUDY
Authors: Angie Botto-van Bemden, Guy Eakin, Rosa Sciortino, Maritza Quintero, Jordi Monfort, Patrick du Souich, Francisco de Abajo, Ingrid Möller, Elizabeth Oswald, Marco Matucci-Cerinic, Deborah Scotton, Marco Bibas, Marianna Vitaloni, Josep Verges
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Globally, osteoarthritis (OA) is the third condition associated with disability. Science holds the key to finding better treatments and a cure. Still, it is essential to learn whats important to patients from the patients to implement the most effective global management of OA. The International Osteoarthritis Task Force, an initiative of the Osteoarthritis Foundation International (Barcelona, Spain) and the Arthritis Foundation (Atlanta, United States) with participation from member organizations in additional countries created the Global Osteoarthritis Patient Perception Survey (GOAPPS)-the first global survey to directly compare quality of life (QoL) &amp; patient perceptions of care in the same OA patient survey across languages and cultures. <h3>Objectives</h3> The goal of the survey was to help all stakeholders in OA healthcare develop a better understanding of patients perceptions and how they may differ between cultures by collecting data on adult OA patient perceptions regarding their OA care. The survey will also collect data on patient demographics, OA symptomology, and impact of OA on daily functioning and QoL. Understanding patients needs and perceptions of care is the first step in optimizing global OA management. <h3>Methods</h3> Observational, cross-sectional study by online survey data collection translated into three languages. We collected data on patient demographics, symptomology, OA impact on daily activity and QoL to investigate the relationship between patient perceptions of their OA care, symptoms and impacts, and QoL. The questionnaire comprised of 4 sections: clinical characteristics, relationship with physicians and treatment, perception of attention, treatment and information received and auto-evaluation of QoL. Inclusion criteria included resident age 18 or older with an OA <h3>Results</h3> A total of 1485 surveys were completed from 7 countries. 1264 surveys were answered in English, 218 in Spanish and 3 in Italian; analysis of cultural differences was unable to be carried out in this pilot. Data show that the majority of the respondents were female (90%) and more than 55 years of age (82%). The majority (73%) of patients had knee OA, followed by hand (57%) and spine (54%). Comorbidities included hypertension (50%) and obesity (43%). Nearly all patients reported limitations related to physical activities (97%), followed by work activities (49%), social interaction (43%) and sex life (23%). 37% of patients experience emotional or mental health issue. The 58% says their doctor adequately explained their diagnosis and 55% understand the treatment options. Importantly, 41% of respondents are not satisfied with their OA treatment and 79% would like access to non-drug/non-surgical treatments. While 52% of respondents rate their QoL as good, 95% would rate it better if their OA was eliminated. <h3>Conclusion</h3> The results emphasize the significant impact of OA disease on patients daily activities and their desire to play an active role in managing their disease. Notably the majority asks for access to additional options for non-drug/non-surgical treatments stressing the need for an OA management improvement. This is a pilot survey and the results do not permit analysis of cultural differences. Continued survey distribution &amp; analysis will determine differences in patient perception of QoL between OA patients living in different countries to further optimize global OA management. <h3>Disclosure of Interests</h3> Angie Botto-van Bemden: None declared, Guy Eakin: None declared, Rosa Sciortino: None declared, Maritza Quintero: None declared, Jordi Monfort Speakers bureau: Bioibrica Procare Health, Patrick du Souich: None declared, Francisco de Abajo: None declared, Ingrid Mller: None declared, Elizabeth Oswald: None declared, Marco Matucci-Cerinic Grant/research support from: Actelion, MSD, Pfizer, BMS, Chemomab, Sanipedia, Speakers bureau: Actelion, BMS; MSD, Janssen, Deborah Scotton: None declared, Marco Bibas: None declared, Marianna Vitaloni: None declared, Josep Verges: None declared